ArticleJournal of translational medicine2025
Multi-omics analysis reveals the crosstalk of epigenetic regulatory networks in cutaneous squamous cell carcinoma progression.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated ATAC-Seq and RNA-Seq Identify ATF3 as a Tumor Suppressor in UVB-Induced Keratinocyte Carcinogenesis.Biology · 2026Article
- Multidimensional immune ecological subtyping identifies RUNX1 as a prognostic factor in uveal melanoma.Discover oncology · 2026Article
- Correction: Multi-omics analysis reveals the crosstalk of epigenetic regulatory networks in cutaneous squamous cell carcinoma progression.Journal of translational medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous squamous cell carcinoma (cSCC) is the second most common form of non-melanoma skin cancer (NMSC), with a steadily increasing global incidence, especially in populations with prolonged ultraviolet (UV) exposure. Advanced or metastatic cSCC carries a poor prognosis, while the application of targeted therapies and immunotherapies remains in the exploratory stage, due to limited understanding of the underlying mechanisms of cSCC occurrence and progression. Epigenetic dysregulation plays important roles in the progression of cSCC. However, how multi-dimensional regulatory networks reshape the epigenetic landscape and contribute to dysregulated gene expression in cSCC remains unclear.
methodsIn this study, we performed parallel RNA m6A sequencing, 850K DNA methylation arrays, whole transcriptome sequencing, and ATAC-seq chromatin accessibility profiling on samples from normal skin, actinic keratosis (AK), and cSCC. We analyzed the regulatory networks and pathways of epigenetic modifications on gene expression. We further explored the crosstalk of epigenetic regulatory networks by correlation analysis. By integrating single-cell RNA-seq data, we identified epigenetically upregulated candidate genes and confirmed their expression and functions with experimental methods.
resultsOur integrated multi-omics analysis provides a comprehensive and dynamic epigenetic map of cSCC progression. Further analysis revealed that DNA methylation and m6A modification jointly regulate gene expression through independent and synergistic ways. The identified epigenetically upregulated candidate genes IDO1, IFI6, and OAS2 were validated to be overexpressed in cSCC tissues and cell lines, and functional assays confirmed their potential key roles in regulating the processes of cell proliferation, migration and invasion in cSCC.
conclusionsBy integrating multi-omics data, this study systematically highlights the multi-layered epigenetic alterations and regulatory mechanisms involved in cSCC development. This multi-stage, multi-omics, and multi-resolution integrated analysis provides a theoretical basis and new insights for future personalized treatment strategies for cSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.